Hyperuricemia, circulating metabolites, and the risk of cardiometabolic multimorbidity.
Uric acid combines with metabolic markers to predict combined heart and metabolic disease risk, potentially refining how doctors use uric acid for risk assessment.
This Clinica Chimica Acta study examines how hyperuricemia and circulating metabolites jointly predict cardiometabolic multimorbidity risk using UK Biobank data (n=422,058), finding mediating metabolic pathways through which uric acid elevations translate to combined cardiovascular-metabolic disease burden. The findings suggest metabolic profiling could improve uric acid-based risk stratification.
What the study was
- Study design
- observational_with_metabolomics
- Population
- UK Biobank participants
- Sample size
- 422058
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Clin Chim Acta
Why it surfaced
Moderate novelty (uric acid + metabolomics for cardiometabolic risk); relevant to cardiometabolic watchlist; Clin Chim Acta is a clinical chemistry journal with moderate impact; scored conservatively as STANDARD given incremental nature of the finding.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.